131. Alexander disease Disease details / Clinical trials / Drug dev / DR info /

Clinical trials : 4 / Drugs : 4 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0

Drugs and their primary sponsors and trial info

2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING
   IONIS PHARMACEUTICALS, INC.
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-IT   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID
   Ionis Pharmaceuticals
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-NL   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-GB   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
ION373
   IONIS PHARMACEUTICALS, INC.
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-IT   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
   Ionis Pharmaceuticals
      2021   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-NL   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-000976-40-GB   Argentina;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   NCT04849741   Canada;Netherlands;United States;